| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T802 |
0-65 |
Sentence |
denotes |
Cholankeril, 202070Stanford University HospitalsCaliforniaDates: |
| T803 |
66-99 |
Sentence |
denotes |
3/4/2020-3/24/2020Last follow-up: |
| T804 |
100-126 |
Sentence |
denotes |
3/24/2020 n = 116Survival: |
| T805 |
127-230 |
Sentence |
denotes |
0.9% died, 86.2% discharged, 4.3% still hospitalized.Inclusion: COVID-19 confirmed based on RT-PCR.Age: |
| T806 |
231-256 |
Sentence |
denotes |
M 50 y (IQR, 35–67 y)Sex: |
| T807 |
257-293 |
Sentence |
denotes |
46.6% femalesGI/liver comorbidities: |
| T808 |
294-337 |
Sentence |
denotes |
2.6% chronic liver diseaseDisease severity: |
| T809 |
338-435 |
Sentence |
denotes |
71.6% evaluated in ED/clinic only, 20.7% admitted to the medical floor, and 7.8% admitted to ICU. |
| T810 |
436-445 |
Sentence |
denotes |
Diarrhea: |
| T811 |
446-499 |
Sentence |
denotes |
10.3% (12)Present on admissionNausea and/or vomiting: |
| T812 |
500-545 |
Sentence |
denotes |
10.3% (12)Present on admissionAbdominal pain: |
| T813 |
546-675 |
Sentence |
denotes |
8.8% (10)Present on admissionNone of the patients had isolated GI symptoms or as the initial symptoms.31.9% reported GI symptoms. |
| T814 |
676-728 |
Sentence |
denotes |
Median duration of GI symptoms was 1 day (IQR, 0–4). |
| T815 |
729-1026 |
Sentence |
denotes |
AST (n = 65)M 35 (IQR, 22–58)In those with any abnormal LFT, M 64 (IQR, 24–76)ALT (n = 65)M 32 (IQR, 22–48)In those with any abnormal LFT, M 59 (IQR, 22–76)Total bilirubin (n = 65)M 0.4 (IQR, 0.3–0.7)In those with any abnormal LFT, M 0.5 (IQR, 0.3–0.7)26 patients developed liver enzyme elevation. |
| T816 |
1027-1072 |
Sentence |
denotes |
22 of them had normal baseline liver enzymes. |
